Abstract
We have recently shown a close correlation between expression of the Multidrug Resistance-associated Protein (MRP) gene and the MYCN oncogene and provided evidence that high MRP expression is a powerful independent predictor of poor outcome in neuroblastoma (Norris et al., New Engl. J. Med., 334, 231 – 238, 1996). The effect of MYCN down-regulation on MRP expression and response to cytotoxic drugs was investigated in NBL-S neuroblastoma cells transfected wtih MYCN antisense RNA constructs. Concomitant with MYCN down-regulation, the level of MRP expression was decreased in the NBAS-4 and NBAS-5 antisense transfectants. These cells demonstrated significantly increased sensitivity to the high affinity MRP substrates vincristine, doxorubicin, sodium arsenate and potassium antimony tartrate, but not to the poor MRP substrates, taxol or cisplatin. Similarly, transfection of full-length MYCN cDNA into SH-EP neuroblastoma cells resulted in increased MRP expression and significantly increased resistance specifically to MRP substrates. The results provide evidence for the MYCN oncogene influencing cytotoxic drug response via regulation of MRP gene expression. Our data also provide a link between the malignant and chemoresistant phenotypes of this childhood malignancy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bordow SB, Haber M, Madafiglio J, Cheung B, Marshall GM and Norris MD. . 1994 Cancer Res. 54: 5036–5040.
Brodeur GM, Azar C, Brother M, Hiemstra J, Kaufman B, Marshall H, Moley J, Nakagawara A, Saylors R, Scavarda N, Schneider S, Wasson J, White P, Seeger RC, Look T and Castleberry R. . 1992 Cancer 70: 1685–1694.
Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM and Deeley RG. . 1992 Science 258: 1650–1654.
Cole SPC, Sparks KE, Fraser K, Loe DW, Grant CE, Wilson GM and Deeley RG. . 1994 Cancer Res. 54: 5902–5910.
Flens MJ, Izquierdo MA, Scheffer GL, Fritz JM, Meijer CJ, Sheper RJ and Zaman GJ. . 1994 Cancer Res. 54: 4557–4563.
Grandori C and Eisenman RN. . 1997 Trends Biochem. Sci. 22: 177–181.
Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SP and Deeley RG. . 1994 Cancer Res. 54: 357–361.
Haber M, Norris MD, Kavallaris M, Bell DR, Davey RA, White L and Stewart BW. . 1989 Cancer Res. 49: 5281–5287.
Lee J-S, Scala S, Matsumoto Y, Dickstein B, Robey R, Zhan Z, Altenberg G and Bates SE. . 1997 J. Cell. Biochem. 65: 513–526.
Norris MD, Bordow SB, Marshall GM, Haber PS, Cohn SL and Haber M. . 1996 N. Engl. J. Med. 334: 231–238.
Norris MD, Bordow SB, Haber PS, Marshall GM, Kavallaris M, Madafiglio J, Cohn SL, Salwen H, Schmidt ML, Hipfner DR, Cole SPC, Deeley RG and Haber M. . 1997 Eur. J. Cancer 33: 1911–1916.
Norris MD, Madafiglio J, Gilbert J, Marshall GM and Haber M. . 1998 Eur. J. Cancer in press.
Raschella G, Romeo A, Negroni A, Pucci S, Dominici C, Castello MA, Bevilacqua P, Felsani A and Calabretta B. . 1994 Cancer Res. 54: 2251–2255.
Ross RA, Spengler BA and Biedler JL. . 1983 J. Natl. Cancer Inst. 71: 741–749.
Schmidt ML, Salwen HR, Manohar CF, Ikegaki N and Cohn SL. . 1994 Cell Growth Differ. 5: 171–178.
Schneider E, Horton JK, Yang C-H, Nakagawa M and Cowan KH. . 1994 Cancer Res. 54: 152–158.
Schwab M, Varmus HE and Bishop JM. . 1985 Nature 316: 160–162.
Spengler BA, Ross RA and Biedler JL. . 1986 Cancer Treat Rep. 70: 959–965.
Stram DO, Matthay KK, O'Leary M, Reynolds CP, Haase GM, Atkinson JB, Brodeur GM and Seeger RC. . 1996 J. Clin. Oncol. 14: 2417–2426.
Weiss WA, Aldape K, Mohapatra G, Feuerstein BG and Bishop JM. . 1997 EMBO J. 16: 2985–2995.
Wenzel A and Schwab M. . 1995 Eur. J. Cancer 31A: 516–519.
Zaman GJR, Flens MJ, van Leusden MR, de Haas M, Mulder HS, Lankelma J, Pinedo HM, Scheper RJ, Baas F, Broxterman HJ and Borst P. . 1994 Proc. Natl. Acad. Sci. USA 91: 8822–8826.
Acknowledgements
This work was supported by grants to M Haber, GM Marshall and MD Norris from the National Health and Medical Research Council, Australia and from the New South Wales State Cancer Council, Australia. ML Schmidt was supported by the Schweppe Foundation, (Chicago, IL, USA) and the Children's Cancer Research Fund, (Los Angeles, CA, USA). SB Bordow and J Gilbert are the recipients of Australian Postgraduate Awards. The Children's Cancer Research Institute is incorporated as the Children's Cancer Institute Australia for Medical Research. The authors are grateful to R Garcia for expert technical assistance.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Haber, M., Bordow, S., Gilbert, J. et al. Altered expression of the MYCN oncogene modulates MRP gene expression and response to cytotoxic drugs in neuroblastoma cells. Oncogene 18, 2777–2782 (1999). https://doi.org/10.1038/sj.onc.1202859
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1202859
Keywords
This article is cited by
-
Novel benzylidene benzofuranone analogues as potential anticancer agents: design, synthesis and in vitro evaluation based on CDK2 inhibition assays
3 Biotech (2022)
-
Conditional expression of retrovirally delivered anti-MYCN shRNA as an in vitro model system to study neuronal differentiation in MYCN-amplified neuroblastoma
BMC Developmental Biology (2011)
-
ATP7A is a novel target of retinoic acid receptor β2 in neuroblastoma cells
British Journal of Cancer (2009)
-
Patched1 deletion increases N-Myc protein stability as a mechanism of medulloblastoma initiation and progression
Oncogene (2009)
-
Microarray analysis reveals differential gene expression patterns and regulation of single target genes contributing to the opposing phenotype of TrkA- and TrkB-expressing neuroblastomas
Oncogene (2005)
